Adam Hunter was scheduled to make his UFC debut at UFC On Fox 21 this past August, but then he was pulled from the card after the United States Anti-Doping Agency (USADA) informed him of a potential anti-doping violation.
It has been announced now by USADA that Hunter has been suspended two years after the drug test revealed the fighter had tested positive for amoxifen metabolite, boldenone metabolites, methandienone metabolites, drostanolone metabolite and clenbuterol.
USADA also released the following statement in regards to the suspension of Hunter:
These non-specified substances are prohibited at all times under the BCAC Anti-Doping Policy and the UFC Anti-Doping Policy, both of which have adopted the World Anti-Doping Agency (WADA) Prohibited List. On the WADA Prohibited List, tamoxifen is a substance in the class of Hormone and Metabolic Modulators, while boldenone, methandienone, drostanolone, and clenbuterol are substances in the class of Anabolic Agents. Under the UFC Anti-Doping Policy, the standard sanction for an anti-doping policy violation involving a non-specified substance is a two-year period of ineligibility.
Hunter’s suspension is a retroactive one, which means that he will be able to compete again on August 11 of 2018-- his failed drug test originally occurred on August 11 of 2016. He last fought in June, earning a win over UFC veteran Chris Dempsey.
Hunter has yet to issue a statement of any kind on the situation and the UFC has yet to issue a statement as well.
